医学
结直肠癌
化疗
肿瘤科
生活质量(医疗保健)
内科学
总体生存率
重症监护医学
癌症
护理部
作者
David Arias Ron,Ruth Vera,Carmen M. Labandeira,María Carmen Areses Manrique,Margarita Ostrowski de Núñez,N. García Cid,Jesús García Mata,Ana Montes
标识
DOI:10.1007/s12094-019-02267-9
摘要
Over the last 2 decades, the standard fluoropyrimidine-based chemotherapy backbone for metastatic colorectal cancer has been complemented by the addition of novel biological agents, achieving impressive increases in 5-year survival rates. Nonetheless, these new combinations have also entailed increases in toxicity, leading to evaluation of de-escalated chemotherapy regimens and "drug holiday" periods in attempts to reduce side effects and optimise quality of life without impairing efficacy. Here, we review the current and emerging evidence for maintenance schedules with chemotherapy and targeted agents, versus continuous treatment after induction treatment, in metastatic colorectal cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI